RDGL · Vivos Inc
$0.05
+0.00 (+1.25%)
At close · Sep 17
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The independent registered public accounting firm has expressed substantial doubt about the Company's ability to continue as a going concern due to limited revenue, nominal cash, and accumulated deficits since inception. Management plans to pursue additional funding through debt and equity financing (including the pending 2026 Regulation A+ Offering), enhance operating performance via strategic focus on core products, process efficiencies, and cost structure improvements. There can be no assurance of success in raising working capital or achieving profitable operations, and the financial statements include no adjustments for outcomes of this uncertainty.”View the 10-Q filed Aug 12, 2026
Market Cap
$22.24M
Shares
494.21M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.05
Open$0.05
Day$0.05–0.05
52W close$0.05–0.09
Avg vol 30d982K
Short int10K · 0.0% float · 1.0d
Short vol3%
DataJan 2020–Sep 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$99,099
Trailing 12 months
Net income (TTM)
−$3.60M
Trailing 12 months
Revenue growth YoY
+142.7%
Year over year
Operating margin
-2,852.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.2%
Year over year · more shares
Price change (1Y)
-48.0%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−29%
below
Price vs 50-day avg
−13%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
2%
near low
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−46%
trailing
YTD return
−29%
this year
Relative strength
−64%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Accumulating
Net +$32.8K over 90 days · 0% sells
Short interest
Falling
0.00% of float · ▼ -87.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Squeeze score
11
low risk · 0–100
Fundamentals
Revenue growth
+23%
Y/Y
Gross margin
-1196%
contracting
EPS growth
0%
Y/Y
Free cash flow
$-2.2M
Balance sheet
$52.6K
net cash
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
10.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−29%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Accumulating
Net +$32.8K over 90 days · 0% sells
Short interest
Falling
0.00% of float · ▼ -87.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 2%
Range high $0
vs 200-day avg -29%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RDGL
this stock
Vivos Inc
|
$22.24M | -29.5% | +144.3% | — | 0.0% |
|
ABT
Abbott Laboratories
|
$177.72B | -18.4% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$119.98B | -3.4% | +8.4% | 23.1 | 0.9% |
|
SYK
Stryker Corp
|
$108.13B | -20.3% | +11.2% | 29.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$64.27B | -54.3% | +12.5% | 18.0 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
1
- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- CAPTRUST FINANCIAL ADVISO…
Held
Float
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RDGL | -2.0% | -14.4% | -45.7% | -5.1% | -29.5% |
| SPY | +0.6% | -0.8% | +18.2% | -0.6% | +11.8% |
| vs SPY | -2.7% | -13.6% | -63.9% | -4.5% | -41.3% |